291 related articles for article (PubMed ID: 31734366)
1. Therapeutic applications of AS1411 aptamer, an update review.
Yazdian-Robati R; Bayat P; Oroojalian F; Zargari M; Ramezani M; Taghdisi SM; Abnous K
Int J Biol Macromol; 2020 Jul; 155():1420-1431. PubMed ID: 31734366
[TBL] [Abstract][Full Text] [Related]
2. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells.
Soundararajan S; Wang L; Sridharan V; Chen W; Courtenay-Luck N; Jones D; Spicer EK; Fernandes DJ
Mol Pharmacol; 2009 Nov; 76(5):984-91. PubMed ID: 19657047
[TBL] [Abstract][Full Text] [Related]
3. Tumor targeting with a (99m)Tc-labeled AS1411 aptamer in prostate tumor cells.
Noaparast Z; Hosseinimehr SJ; Piramoon M; Abedi SM
J Drug Target; 2015; 23(6):497-505. PubMed ID: 25673264
[TBL] [Abstract][Full Text] [Related]
4. Aptamer-based Targeted Delivery of a G-quadruplex Ligand in Cervical Cancer Cells.
Carvalho J; Paiva A; Cabral Campello MP; Paulo A; Mergny JL; Salgado GF; Queiroz JA; Cruz C
Sci Rep; 2019 May; 9(1):7945. PubMed ID: 31138870
[TBL] [Abstract][Full Text] [Related]
5. Nucleolin-targeted Extracellular Vesicles as a Versatile Platform for Biologics Delivery to Breast Cancer.
Wang Y; Chen X; Tian B; Liu J; Yang L; Zeng L; Chen T; Hong A; Wang X
Theranostics; 2017; 7(5):1360-1372. PubMed ID: 28435471
[TBL] [Abstract][Full Text] [Related]
6. AS1411 binds to nucleolin via its parallel structure and disrupts the exos-miRNA-27a-mediated reciprocal activation loop between glioma and astrocytes.
Sun X; Zhang W; Gou C; Wang X; Wang X; Shao X; Chen X; Chen Z
Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167211. PubMed ID: 38701957
[TBL] [Abstract][Full Text] [Related]
7. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism.
Reyes-Reyes EM; Teng Y; Bates PJ
Cancer Res; 2010 Nov; 70(21):8617-29. PubMed ID: 20861190
[TBL] [Abstract][Full Text] [Related]
8. Cell Surface Nucleolin as a Promising Receptor for Effective AS1411 Aptamer-Mediated Targeted Drug Delivery into Cancer Cells.
Mosafer J; Mokhtarzadeh A
Curr Drug Deliv; 2018; 15(9):1323-1329. PubMed ID: 30039760
[TBL] [Abstract][Full Text] [Related]
9. G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms.
Bates PJ; Reyes-Reyes EM; Malik MT; Murphy EM; O'Toole MG; Trent JO
Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt B):1414-1428. PubMed ID: 28007579
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic studies of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation.
Reyes-Reyes EM; Šalipur FR; Shams M; Forsthoefel MK; Bates PJ
Mol Oncol; 2015 Aug; 9(7):1392-405. PubMed ID: 25911416
[TBL] [Abstract][Full Text] [Related]
11. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer.
Hwang DW; Ko HY; Lee JH; Kang H; Ryu SH; Song IC; Lee DS; Kim S
J Nucl Med; 2010 Jan; 51(1):98-105. PubMed ID: 20008986
[TBL] [Abstract][Full Text] [Related]
12. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells.
Soundararajan S; Chen W; Spicer EK; Courtenay-Luck N; Fernandes DJ
Cancer Res; 2008 Apr; 68(7):2358-65. PubMed ID: 18381443
[TBL] [Abstract][Full Text] [Related]
13. Aptamer-based microcantilever biosensor for ultrasensitive detection of tumor marker nucleolin.
Li H; Bai X; Wang N; Chen X; Li J; Zhang Z; Tang J
Talanta; 2016 Jan; 146():727-31. PubMed ID: 26695322
[TBL] [Abstract][Full Text] [Related]
14. Nucleolin Overexpression Confers Increased Sensitivity to the Anti-Nucleolin Aptamer, AS1411.
Sharma VR; Thomas SD; Miller DM; Rezzoug F
Cancer Invest; 2018; 36(9-10):475-491. PubMed ID: 30396283
[TBL] [Abstract][Full Text] [Related]
15. Aptamer-Aptamer Chimera for Targeted Delivery and ATP-Responsive Release of Doxorubicin into Cancer Cells.
Esawi E; Alshaer W; Mahmoud IS; Alqudah DA; Azab B; Awidi A
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884745
[TBL] [Abstract][Full Text] [Related]
16. Cell surface nucleolin as active bait for nanomedicine in cancer therapy: a promising option.
Ferrara B; Belbekhouche S; Habert D; Houppe C; Vallée B; Bourgoin-Voillard S; Cohen JL; Cascone I; Courty J
Nanotechnology; 2021 May; 32(32):. PubMed ID: 33892482
[TBL] [Abstract][Full Text] [Related]
17. Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14.
Cho Y; Lee YB; Lee JH; Lee DH; Cho EJ; Yu SJ; Kim YJ; Kim JI; Im JH; Lee JH; Oh EJ; Yoon JH
PLoS One; 2016; 11(8):e0160822. PubMed ID: 27494117
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of somatostatin and nucleolin receptors for therapeutic delivery in non-small cell lung cancer stem cells applying the somatostatin-analog DOTATATE and the nucleolin-targeting aptamer AS1411.
Holmboe S; Hansen PL; Thisgaard H; Block I; Müller C; Langkjær N; Høilund-Carlsen PF; Olsen BB; Mollenhauer J
PLoS One; 2017; 12(5):e0178286. PubMed ID: 28542563
[TBL] [Abstract][Full Text] [Related]
19. Nucleolin on the cell surface as a new molecular target for gastric cancer treatment.
Watanabe T; Hirano K; Takahashi A; Yamaguchi K; Beppu M; Fujiki H; Suganuma M
Biol Pharm Bull; 2010; 33(5):796-803. PubMed ID: 20460757
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma.
Rosenberg JE; Bambury RM; Van Allen EM; Drabkin HA; Lara PN; Harzstark AL; Wagle N; Figlin RA; Smith GW; Garraway LA; Choueiri T; Erlandsson F; Laber DA
Invest New Drugs; 2014 Feb; 32(1):178-87. PubMed ID: 24242861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]